Neogenomics Logo
Menu

Neo Comprehensive - Myeloid Disorders

  • Next Generation Sequencing (NGS)

The Neo Comprehensive- Myeloid Disorders assay analyzes 164 genes to detect DNA and RNA alterations through next-generation sequencing (NGS) as noted below. Test reports include a summary interpretation of all results together.

DNA sequencing SNVs/Indels (127 genes):
ABL1, ANKRD26, APC, ARAF, ASXL1, ATM, ATRX, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CHEK2, CSF3R, CTC1, CUX1, CXCR4, DDX41, DKC1, DNMT3A, ELANE, EPCAM, ERCC4, ETNK1, ETV6, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FLT3, G6PC3, GATA1, GATA2, GFI1, GNAS, GNB1, HAX1, HRAS, IDH1, IDH2, IKZF1, IKZF3, ITPKB, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MAP2K1, MET, MLH1, MPL, MSH2, MSH6, MYD88, NF1, NHP2, NOP10, NOTCH1, NPM1, NRAS, PALB2, PDGFRA, PHF6, PIGA, PML, PMS2, PRPF8, PPM1D, PTEN, PTPN11, RAD21, RAD51C, RB1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS26, RPS7, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SLX4, SMC1A, SMC3, SRP72, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TERC, TERT, TET2, TINF2, TP53, U2AF1, VHL, WAS, WRAP53, WT1, ZRSR2

Copy Number Variants (CNV) (17 genes):
ABL1, ASXL1, ATG2B, BRAF, CBFB, CDKN1B, CDKN2A, DNMT1, ETV6, EZH2, GSKIP, JAK2, KMT2A, KRAS, MYC, RAD21, TP53

RNA sequencing Fusions (40 genes):
ABL1, AFDN, AFF1, ALK, BCL11B, CBFB, CEP43, CPSF6, CREBBP, DEK, ELL, EP300, ETV6, FGFR1, FLT3, GLIS2, JAK2, KMT2A, MECOM, MLLT1, MLLT3, MRTFA, MYB, MYH11, NTRK3, NUP214, NUP98, PCM1, PDGFRA, PDGFRB, PICALM, PML, PRDM16, RARA, RBM15, RPN1, RUNX1, RUNX1T1, TCF3, ZNF384

Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the Neo Comprehensive Myeloid Disorders. It is reported separately from the Neo Comprehensive profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.

Turnaround time
14 Days

Level of Service

  • Global
New York Approved: Yes

Clinical Significance

The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.

Specimen Requirements

Bone Marrow Aspirate: 2-3 mL in EDTA tube. Sodium heparin is acceptable.
Peripheral Blood: 3-5 mL in EDTA tube. Sodium heparin is acceptable.
H&E slide: Required, plus paraffin block.
Cut Slides: H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.
Note on FFPE: Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Do not use: Mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
Note on fresh samples: NeoGenomics should receive within 7 days from collection for acceptable cell viability.
Note: Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.

Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - TNA if specimen hold service is desired.

CPT Code(s)*

81455

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.

Biomarkers

DNA Sequencing
SNVs + Indels
PRPF8SUZ12WT1CBLBCBLCABL1
CDKN2AETNK1FANCBFANCMFLT3GNB1
IKZF1JAK2JAK3IKZF3ITPKBANKRD26
PDGFRASH2B3TP53ASXL1BCORBRAF
CEBPACSF3RDNMT3AETV6EZH2CALR
PIGAIDH1KITHRASKRASNPM1
NRASPHF6PMLPTPN11IDH2SETBP1
SF3B1SRSF2STAG2TET2U2AF1ZRSR2
BRCA2BRIP1RTEL1CTC1DDX41SAMD9
ELANESAMD9LSBDSDKC1ERCC4G6PC3
GFI1HAX1NHP2NOP10CUX1PALB2
RAD51CRPL11RPL35ARPL5RPS10RPS17
RPS26RPS7SLX4SRP72TERCTERT
TINF2WASWRAP53ATMBRCA1CHEK2
FANCAFANCCFANCD2FANCEFANCFFANCI
FANCLFANCGMETMLH1MSH2MSH6
PMS2PTENAPCCXCR4MYD88NOTCH1
EPCAMFBXW7ATRXARAFBCORL1BLM
CBLGATA1GATA2GNASKDM6AMAP2K1
MPLPPM1DNF1RAD21RB1KMT2A
SETD2SMC1ASMC3STAT3STAT5BVHL
RUNX1
CNVs
ABL1ASXL1CDKN1BDNMT1CDKN2AETV6
EZH2KMT2ATP53RAD21ATG2BGSKIP
JAK2KRAS
RNA Sequencing
Fusions
MYBBCL11BCBFBCEP43CPSF6MYH11
DEKABL1EP300ETV6FGFR1FLT3
JAK2AFDNAFF1KMT2ANTRK3NUP98
PDGFRAMECOMPDGFRBMRTFARUNX1TCF3
ZNF384RBM15RPN1CREBBPELLGLIS2
MLLT1MLLT3NUP214PCM1PMLRARA
RUNX1T1PICALMPRDM16ALK
Fluorescence In Situ Hybridization (FISH)
CNVs
CBFB
Structural Rearrangement(s)
BRAF
Amplification(s)
MYC

Last Updated: October 20, 2025

Get in touch

Our Client Services team is on hand to help. Please call us at 866.776.5907, Option 3.